Loading organizations...
ProQuest Investments operates as a dedicated venture capital firm, specializing in providing capital to companies across the healthcare sector from early to late-stage development. The firm focuses on identifying and supporting enterprises driving innovation, with particular emphasis on therapeutics, including advancements in drug discovery and molecular analysis, targeting critical unmet medical needs.
Established in 1998, the firm was founded by individuals such as Jay Moorin and Jeremy Goldberg. Their insight centered on creating a specialized investment platform to support the burgeoning healthcare industry's scientific and technological breakthroughs, leveraging deep understanding of financial markets and healthcare innovation. This foundation aimed to foster significant advancements.
ProQuest Investments partners with diverse healthcare companies, offering financial backing and strategic guidance to foster growth. The firm’s enduring vision is to cultivate exceptional businesses that advance medical science and improve patient care. Through collaborative, long-term partnerships, ProQuest Investments seeks to propel significant healthcare solutions forward.
ProQuest Investments has 3 tracked investments across 3 companies. The latest tracked deal is $49.0M Series C in Immune Design in October 2013.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Oct 1, 2013 | Immune Design | $49.0M Series C | Peter Svennilson, Topspin Partners | MPM Capital, Osage University Partners, Versant Ventures, Alta Partners, Richard Kenney, MD, Osage Venture Partners, Bernard Davitian |
| Jul 1, 2012 | Mersana Therapeutics | $27.0M Series A | Sara Nayeem | Avoro Ventures, OrbiMed, Versant Ventures, Elliott Sigal, F Prime Capital, Harris & Harris Group, RHO Ventures |
| Jul 1, 2012 | Agile Therapeutics | $40.0M Series C | Andrew Schiff | Aisling Capital, Morgenthaler Ventures, Novo Ventures, Care Capital, Investor Growth Capital, Kaiser Permanente Ventures, Novitas Capital |